Lokon Pharma Announces Collaboration to Combine LOAd703 with BeiGene’s Tislelizumab
Lokon Pharma Announces Collaboration to Combine its TME Gene Engineering Product with Anti-PD-1 Antibody Tislelizumab in Pancreatic Cancer
Overview
Lokon Pharma AB has initiated a clinical collaboration to combine in a randomized Phase 2 trial Lokon’s tumor microenvironment (TME) gene engineering product, LOAd703, with BeiGene’s anti-PD-1 antibody tislelizumab in patients with pancreatic cancer.
Words From The CEO: Lokon Pharma
- We are excited to share the news that LOAd703 will be combined with tislelizumab and chemotherapy in our next randomized phase 2 clinical trial enrolling patients with stage 4 pancreatic cancer”, said Dr. Angelica Loskog, the CEO of Lokon Pharma.
- She continues, “Pancreatic cancer is considered not sensitive to immunotherapy with checkpoint blockade antibodies, but gene engineering of the TME with LOAd703 inflames the tumor which makes the LOAd703 and tislelizumab combination therapy highly relevant”.
About The LOAd703
- LOAd703 has been evaluated in a phase 1/2 trial in combination with an anti- PD-L1 antibody and chemotherapy in pancreatic cancer, and in combination with an anti-PD-L1 antibody in refractory melanoma, as previously announced.
- The melanoma data was orally presented at the ESMO annual conference, on 13thSeptember 2024, in which the capacity of LOAd703 to inflame the TME was demonstrated leading to tumor effect in patients that were previously progressing on checkpoint blockade treatment”.
About Lokon Pharma
- Lokon Pharma AB is a leading Swedish biotech company in the rapidly expanding field of tumor microenvironment gene engineering and is focused on the clinical development of its first, virus-based, product, LOAd703, for cancers with high unmet medical need.
- LOAd703 (delolimogene mupadenorepvec), is the first clinical candidate from the LOAd platform.
